Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers, health plans, health systems, and other entities in approximately 100 countries worldwide.
Read More…
Industry, Sector and Symbol
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
Phone203-635-2002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$417.91 million
Profitability
Miscellaneous
Employees2,000
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable
Teladoc Health (NYSE:TDOC) Frequently Asked Questions
What is Teladoc Health's stock symbol?
Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc Health's earnings last quarter?
Teladoc Health Inc (NYSE:TDOC) released its quarterly earnings results on Wednesday, July, 31st. The health services provider reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. The health services provider earned $130.30 million during the quarter, compared to the consensus estimate of $129.54 million. Teladoc Health had a negative return on equity of 10.64% and a negative net margin of 21.85%. The company's revenue for the quarter was up 37.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) EPS. View Teladoc Health's Earnings History.
When is Teladoc Health's next earnings date?
How can I listen to Teladoc Health's earnings call?
Teladoc Health will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Teladoc Health issued on next quarter's earnings?
Teladoc Health updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $(1.52)-(1.60) for the period, compared to the Thomson Reuters consensus estimate of ($1.52). The company issued revenue guidance of $538-545 million, compared to the consensus revenue estimate of $541.39 million.
What price target have analysts set for TDOC?
15 Wall Street analysts have issued 12 month price targets for Teladoc Health's shares. Their forecasts range from $65.00 to $100.00. On average, they expect Teladoc Health's share price to reach $81.08 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for Teladoc Health.
What is the consensus analysts' recommendation for Teladoc Health?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 1 hold rating and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teladoc Health.
What are Wall Street analysts saying about Teladoc Health stock?
Here are some recent quotes from research analysts about Teladoc Health stock:
- 1. According to Zacks Investment Research, "Teladoc Health’s first-quarter 2019 loss of 43 cents per share was narrower than the Zacks Consensus Estimate of 44 cents per share, but was wider than the year-ago quarter’s loss of 39 cents per share. The loss can be attributed to higher operating expenses than revenues. Its shares have outperformed the industry in a year’s time. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Its international expansion is also impressive. Nevertheless, the company has incurred significant losses and has been unable to generate cash from operations. Its struggle may continue in the coming quarters too. Its high debt level caused a spike in interest expenses, which weighs on operating margins." (5/3/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on TDOC shares. Our price target is $70. After the close on Tuesday, April 30, TDOC reported 1Q18 results that were in line with our estimates and reaffirmed its 2019 guidance. Organic revenue growth was 23% compared with 31% in 4Q18. Importantly, the company indicated that it has expanded its relationship with UnitedHealthcare (UNH – Overweight). The company reiterated that it should be able to maintain organic revenue growth in the 20-30% range next year. The company remains optimistic on Medicare Advantage (MA) plans, but expects more ratable adoption over time. On the surface, TDOC is executing nicely on its virtual health strategy." (4/30/2019)
Has Teladoc Health been receiving favorable news coverage?
News stories about TDOC stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teladoc Health earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the health services provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Teladoc Health.
Are investors shorting Teladoc Health?
Teladoc Health saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 25,830,000 shares, an increase of 7.8% from the August 30th total of 23,970,000 shares. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is presently 19.6 days. Approximately 36.3% of the shares of the company are sold short. View Teladoc Health's Current Options Chain.
Who are some of Teladoc Health's key competitors?
Some companies that are related to Teladoc Health include Centene (CNC), ResMed (RMD), AmerisourceBergen (ABC), Fresenius Medical Care AG & Co. KGaA (FME), Sino Biopharmaceutical (SBMFF), OLYMPUS CORP/S (OCPNY), Align Technology (ALGN), Laboratory Corp. of America (LH), Incyte (INCY), Sunny Optical Technology (Group) (SNPTF), Teleflex (TFX), Merck KGaA (MKGAF), Cardinal Health (CAH), SONOVA HLDG AG/ADR (SONVY) and Eisai (ESALY).
What other stocks do shareholders of Teladoc Health own?
Who are Teladoc Health's key executives?
Teladoc Health's management team includes the folowing people:
- Mr. Jason Nathanial Gorevic, CEO & Director (Age 47)
- Mr. Peter A. McClennen, Pres & Interim COO (Age 50)
- Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 44)
- Ms. Stephany Verstraete, Chief Marketing Officer (Age 50)
- Dr. George Byron Brooks BS EE, M.D., Co-Founder
When did Teladoc Health IPO?
(TDOC) raised $112 million in an IPO on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Teladoc Health's major shareholders?
Teladoc Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (2.43%), Peregrine Capital Management LLC (0.80%), Artemis Investment Management LLP (0.18%), Envestnet Asset Management Inc. (0.14%), Landsberg Bennett & Dubbaneh LLC (0.05%) and Avitas Wealth Management LLC (0.04%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen and Stephany Verstraete. View Institutional Ownership Trends for Teladoc Health.
Which major investors are selling Teladoc Health stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Artemis Investment Management LLP, Jaffetilchin Investment Partners LLC, Riverbridge Partners LLC, Crow Point Partners LLC, Landsberg Bennett & Dubbaneh LLC and Advantage Investment Management LLC. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein, Michelle Bucaria and Peter A Mcclennen. View Insider Buying and Selling for Teladoc Health.
Which major investors are buying Teladoc Health stock?
TDOC stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Envestnet Asset Management Inc., Avitas Wealth Management LLC, Ford Financial Group Inc., Coastal Investment Advisors Inc., Gradient Investments LLC, Brinker Capital Inc. and Truvestments Capital LLC. View Insider Buying and Selling for Teladoc Health.
How do I buy shares of Teladoc Health?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teladoc Health's stock price today?
One share of TDOC stock can currently be purchased for approximately $70.04.
How big of a company is Teladoc Health?
Teladoc Health has a market capitalization of $5.05 billion and generates $417.91 million in revenue each year. The health services provider earns $-97,080,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Teladoc Health employs 2,000 workers across the globe.View Additional Information About Teladoc Health.
What is Teladoc Health's official website?
How can I contact Teladoc Health?
Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc Health (NYSE TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc Health and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
